Table 2 The effect of KAT and KADC inhibitors on EMT in different cancer cells
From: Regulation of epithelial-mesenchymal transition by protein lysine acetylation
Drug name | Drug types | KAT or HDAC specificity | Target cancer cells | The role on EMT | References |
|---|---|---|---|---|---|
Anacardic acid | KAT inhibitor | Non-selective KAT inhibitor | Breast cancer, Prostate cancer | Inhibit | |
Garcinol | KAT inhibitor | P300 inhibitor | Breast cancer | Inhibit | [104] |
EGCG | KAT inhibitor | P300/CBP inhibitor | Lung cancer | Inhibit | |
ICG-001 | KAT inhibitor | CBP/β-catenin inhibitor | Nasopharyngeal carcinoma | Inhibit | [105] |
Mocetinostat | HDAC inhibitor | class I KADC inhibitor | Pancreatic cancer, Lung cancer | Inhibit | [106] |
SAHA | HDAC inhibitor | class I, II and IV, KADC inhibitor | Head and neck cancer, Triple-negative breast cancer, Breast mesenchymal cancer | Inhibit | |
TSA | HDAC inhibitor | class I, II and IV, KADC inhibitor | Breast cancer, Lung cancer | Inhibit | |
Sodium butyrate | HDAC inhibitor | Class I, II KADC inhibitor | HCC, Colorectal cancer, Bladder cancer | Inhibit | |
VPA | HDAC inhibitor | Class I, II KADC inhibitor | Gastric Cancer, HCC, Prostate carcinoma, Renal cell carcinoma, Esophageal squamous cell carcinoma, Prostate carcinoma | Inhibit | |
MS-275 | HDAC inhibitor | Class I KADC inhibitor | Breast cancer, Non-small cell lung cancer | Inhibit | |
LBH589 | HDAC inhibitor | pan-KADC inhibitor | Colorectal cancer, Breast cancer, Prostate cancer, HCC | Inhibit | |
TSA | HDAC inhibitor | class I, II and IV, KADC inhibitor | Esophageal squamous | Activate | [129] |
SAHA | HDAC inhibitor | class I, II and IV, KADC inhibitor | Prostate cancer, Lung cancer, Gastric cancer, Triple negative Breast cancer | Activate | |
VPA | HDAC inhibitor | Class I, II KADC inhibitor | Colorectal cancer, Triple negative breast cancer, Breast cancer, HCC, Colon carcinoma | Activate |